1. Home
  2. OLP vs CAPR Comparison

OLP vs CAPR Comparison

Compare OLP & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo One Liberty Properties Inc.

OLP

One Liberty Properties Inc.

N/A

Current Price

$23.10

Market Cap

550.9M

Sector

Real Estate

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$8.82

Market Cap

584.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OLP
CAPR
Founded
1982
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
550.9M
584.9M
IPO Year
1995
2011

Fundamental Metrics

Financial Performance
Metric
OLP
CAPR
Price
$23.10
$8.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$26.75
$44.63
AVG Volume (30 Days)
50.1K
7.5M
Earning Date
05-05-2026
05-12-2026
Dividend Yield
7.88%
N/A
EPS Growth
N/A
N/A
EPS
1.00
N/A
Revenue
$82,740,000.00
N/A
Revenue This Year
$11.98
N/A
Revenue Next Year
$3.71
$3.31
P/E Ratio
$23.20
N/A
Revenue Growth
1.02
N/A
52 Week Low
$19.62
$2.96
52 Week High
$25.88
$40.37

Technical Indicators

Market Signals
Indicator
OLP
CAPR
Relative Strength Index (RSI) 37.19 47.13
Support Level $23.31 $3.35
Resistance Level $23.63 $11.00
Average True Range (ATR) 0.42 0.94
MACD -0.08 0.30
Stochastic Oscillator 16.42 42.93

Price Performance

Historical Comparison
OLP
CAPR

About OLP One Liberty Properties Inc.

One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: